Herbert Rudolf Treutlein

Title: Herbert Rudolf Treutlein: Innovator in Kinase Inhibitors

Introduction

Herbert Rudolf Treutlein is a notable inventor based in Moonee Ponds, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective kinase inhibitors. With a total of six patents to his name, Treutlein's work has the potential to impact various medical treatments.

Latest Patents

One of Treutlein's latest patents is focused on benzimidazoles as selective kinase inhibitors. This patent describes a compound of the general formula (I) or its pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms, or diastereomers. The compound features a variety of six-membered nitrogen-containing heterocyclic rings and offers methods for treating tyrosine kinase-associated disease states. Another significant patent involves a method of designing agonists and antagonists to the EGF receptor family. This invention relates to compounds that can bind to the EGF receptor and modulate its activity based on the 3-D structure coordinates of the receptor crystal.

Career Highlights

Throughout his career, Treutlein has worked with various organizations, including the Commonwealth Scientific and Industrial Research Organisation. His innovative work has led to advancements in the understanding and treatment of diseases associated with tyrosine kinases.

Collaborations

Treutlein has collaborated with notable individuals in his field, including Frank Koentgen and Gabriele Maria Suess. These collaborations have contributed to the development of his patents and the advancement of pharmaceutical research.

Conclusion

Herbert Rudolf Treutlein is a distinguished inventor whose work in kinase inhibitors and receptor modulation has the potential to transform medical treatments. His contributions to the field are significant and continue to influence pharmaceutical research and development.